Storia in 3 fonti

FDA OKs Immunotherapy-BCG Combo for High-Risk Bladder Cancer

Combination significantly improved disease-free survival in phase III trial

Raccontata da

healio.com

medpagetoday.com

morningstar.com

Confronto fonti

3 prospettive sulla stessa storia

AI · summaries

medpagetoday.comStai leggendo3 mesi fa

FDA OKs Immunotherapy-BCG Combo for High-Risk Bladder Cancer

Combination significantly improved disease-free survival in phase III trial

originale

healio.com3 mesi fa

Imfinzi combination snags FDA approval for high-risk non-muscle invasive bladder cancer

The FDA has approved an immunotherapy combination therapy for adult patients with Bacillus Calmette-Guérin-naive, high-risk non-muscle invasive bladder cancer.The combination of durvalumab (Imfinzi, AstraZeneca) plus…

Leggi questa versione → originale

Timeline cronologica

giovedì 28 maggio 2026·healio.com
Imfinzi combination snags FDA approval for high-risk non-muscle invasive bladder cancer
The FDA has approved an immunotherapy combination therapy for adult patients with Bacillus Calmette-Guérin-naive, high-risk non-muscle invasive bladder cancer.The combination of…
giovedì 28 maggio 2026·medpagetoday.com
FDA OKs Immunotherapy-BCG Combo for High-Risk Bladder Cancer
Combination significantly improved disease-free survival in phase III trial

FDA OKs Immunotherapy-BCG Combo for High-Risk Bladder Cancer

Confronto fonti

FDA OKs Immunotherapy-BCG Combo for High-Risk Bladder Cancer

Imfinzi combination snags FDA approval for high-risk non-muscle invasive bladder cancer

Timeline cronologica

Imfinzi combination snags FDA approval for high-risk non-muscle invasive bladder cancer

FDA OKs Immunotherapy-BCG Combo for High-Risk Bladder Cancer

IMFINZI® (durvalumab) approved in the US in first and only immunotherapy combination for patients with…

IMFINZI® (durvalumab) approved in the US in first and only immunotherapy combination for patients with BCG-naïve, high-risk…